CANCER Publishes Study Demonstrating Substantial Disease Burden for Patients with Systemic Mastocytosis

/PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced two publications in the medical journal CANCER describing results from the...

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,United States ,Ruben Mesa ,Becker Hewes ,Touchstone Sm Patient ,Mays Cancer Center ,Linkedin ,Exchange Commission ,Prnewswire Blueprint Medicines Corporation ,Ut Health San Antonio ,Touchstone Healthcare Provider ,Cancer Support Community ,Mast Cell Disease Society ,Medicines Corporation ,Blueprint Medicines ,Cancer Support ,San Antonio ,Chief Medical Officer ,Blueprint Medicine Mast Cell Connect Registry ,Work Productivity ,Activity Impairment ,Outcomes Among Patients ,Systemic Mastocytosis ,Routine Clinical Practice ,Patient Disease Burden ,Management Approaches ,Touchstone Healthcare Provider Survey ,Private Securities Litigation Reform Act ,Blueprint Medicine ,Annual Report ,Quarterly Report ,Blueprint Medicines Corporation ,